Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
436 stopped studies mapped to Squamous Cell Carcinoma and descendants · 91% state a reason
Over the 436 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01484769 | Method Development and Assessment of the Effects of Tobacco Products on Oral Cavity Cells(H&N) | — | withdrawn | Dec 2, 2011 | University of Louisville | not stated | Not stated |
| NCT00490061 | Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot… | Phase 2 | terminated | Jun 22, 2007 | Quynh-Thu Le | Poor accrual. | Enrollment / accrual |
| NCT00443261 | Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell… | Phase 1 | terminated | Mar 5, 2007 | University of Kansas Medical Center | Accrual problems | Enrollment / accrual |
| NCT00903461 | Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck… | Phase 1 | terminated | May 18, 2009 | University of Pittsburgh | drug supply issues | Drug supply |
| NCT00937612 | Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk | N/A | terminated | Jul 13, 2009 | Chang Gung Memorial Hospital | Study group showed better results. Poor Accrual. | Enrollment / accrual |
| NCT02331875 | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the… | Phase 1 / Phase 2 | terminated | Jan 6, 2015 | Innate Pharma | lack of recruitment | Enrollment / accrual |
| NCT01283178 | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced… | Phase 1 | terminated | Jan 25, 2011 | Virginia Commonwealth University | The study was terminated. The data analysis was futile with only 3 accruals. PI opted to terminate… | Enrollment / accrual |
| NCT02279576 | Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)(PAZOPEN-SOGUG) | Phase 2 | terminated | Oct 31, 2014 | Spanish Oncology Genito-Urinary Group | The low recruitment of patients will not allow to complete the study with the required number of… | Enrollment / accrual |
| NCT02649530 | A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous… | Phase 2 | withdrawn | Jan 7, 2016 | University of Michigan Rogel Cancer Center | funding withdrawn | Funding |
| NCT00190554 | A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous… | Phase 3 | terminated | Sep 19, 2005 | Japan Clinical Oncology Group | not stated | Not stated |
| NCT01975688 | A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis | Phase 1 | terminated | Nov 5, 2013 | GW Pharmaceuticals Ltd | Slow recruitment | Enrollment / accrual |
| NCT01820312 | A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) | Phase 2 | withdrawn | Mar 28, 2013 | University of Arkansas | Due to no enrollment. | Enrollment / accrual |
| NCT01528137 | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer… | Phase 1 | terminated | Feb 7, 2012 | Stanford University | Negative data from another trial led to termination of this trial by sponsor. | Other (stated, no rule matched) |
| NCT02334319 | Ganetespib Window of Opportunity Study in Head and Neck Cancers | Phase 1 | terminated | Jan 8, 2015 | Emory University | Lack of funding | Funding |
| NCT00627835 | Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and… | Phase 1 | withdrawn | Mar 3, 2008 | British Columbia Cancer Agency | Site decided not to open this study | Other (stated, no rule matched) |
| NCT00377247 | Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With… | Phase 1 | terminated | Sep 18, 2006 | University of Pittsburgh | study closed to accrual due to slow accrual | Enrollment / accrual |
| NCT02119728 | Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the… | Phase 2 | withdrawn | Apr 22, 2014 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02143622 | Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell… | Phase 1 / Phase 2 | withdrawn | May 21, 2014 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical…(iNSITE2) | Phase 2 | terminated | Jun 24, 2015 | BIND Therapeutics | not stated | Not stated |
| NCT02059252 | Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold | Phase 1 / Phase 2 | terminated | Feb 11, 2014 | Smart Matrix Limited | Mode of application to be reconsidered by Sponsor | Other (stated, no rule matched) |
| NCT01285635 | A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head… | Phase 2 | terminated | Jan 28, 2011 | University of Michigan Rogel Cancer Center | drug is no longer manufactured | Drug supply |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | Phase 2 | withdrawn | Dec 18, 2013 | Centre Leon Berard | Industry decline to supply study drug | Drug supply |
| NCT01161498 | Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy… | Phase 3 | terminated | Jul 13, 2010 | BioVex Limited | The changing aetiology of squamous cell carcinoma of the head and neck (SCCHN). | Other (stated, no rule matched) |
| NCT01532453 | Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ… | Phase 3 | terminated | Feb 14, 2012 | Spirig Pharma Ltd. | For futility reasons and potential "loss of chance" for MD 3511356 group | Efficacy / futility |
| NCT00272181 | Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer | Phase 2 | terminated | Jan 4, 2006 | Sesen Bio, Inc. | Slow accrual in North America | Enrollment / accrual |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients… | Phase 2 / Phase 3 | terminated | Dec 18, 2006 | Sesen Bio, Inc. | Corporate reasons unrelated to safety and efficacy | Safety / toxicity |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell… | Phase 1 / Phase 2 | withdrawn | Sep 1, 2015 | Erin Bertino | PI decision due to funding support | Funding |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With… | Phase 1 / Phase 2 | terminated | Jan 23, 2014 | Otsuka Novel Products GmbH | not stated | Not stated |
| NCT01963715 | A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | Phase 1 | terminated | Oct 16, 2013 | ImmunoGen, Inc. | not stated | Not stated |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | Phase 1 / Phase 2 | withdrawn | Apr 26, 2012 | Dana-Farber Cancer Institute | Local IRB closed the study due to poor accural. | Other (stated, no rule matched) |
| NCT01949740 | Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA… | — | terminated | Sep 24, 2013 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT01009203 | Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible,… | Phase 2 | terminated | Nov 6, 2009 | New Mexico Cancer Research Alliance | High patient withdrawal rate | Other (stated, no rule matched) |
| NCT02507076 | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma… | N/A | withdrawn | Jul 23, 2015 | Albert Einstein College of Medicine | no enrollment | Enrollment / accrual |
| NCT02162641 | Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer(R-SeNSAR) | — | withdrawn | Jun 13, 2014 | The Christie NHS Foundation Trust | The study was terminated early as it failed to recruit. | Enrollment / accrual |
| NCT02156180 | Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma | — | suspended | Jun 5, 2014 | Queensland Centre of Excellence for Head and Neck Cancer | Awaiting funding to facilitate selected-ion flow-tube mass spectrometry (SIFT/MS) | Funding |
| NCT00073450 | Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and… | Phase 2 | terminated | Nov 24, 2003 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT02023541 | Proton Beam Therapy to Treat Esophageal Cancer | Phase 1 | terminated | Dec 30, 2013 | Washington University School of Medicine | Lack of insurance coverage for proton beam treatment | Other (stated, no rule matched) |
| NCT01953952 | Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage… | Phase 2 | withdrawn | Oct 1, 2013 | Radiation Therapy Oncology Group | Slow accrual | Enrollment / accrual |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients… | Phase 1 | withdrawn | Feb 11, 2014 | Virginia Commonwealth University | Due to no accrual. | Enrollment / accrual |
| NCT01133262 | Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET)… | — | withdrawn | May 28, 2010 | Washington University School of Medicine | Feasibility/pilot study of 5 subjects registration not required | Other (stated, no rule matched) |
| NCT02033538 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell… | Phase 2 | withdrawn | Jan 10, 2014 | Zhejiang University | This clinical trial was closed due to slow recruitment of patients. | Enrollment / accrual |
| NCT02034968 | Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced… | Phase 2 | withdrawn | Jan 14, 2014 | Zhejiang University | No recruitment | Enrollment / accrual |
| NCT02041819 | Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of… | Phase 2 | withdrawn | Jan 22, 2014 | Zhejiang University | No recruitment | Enrollment / accrual |
| NCT02011594 | Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma | Phase 2 | withdrawn | Dec 13, 2013 | Zhejiang University | There was no participants enrolled in this clinical trial. | Enrollment / accrual |
| NCT01333852 | Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer(METTAX) | Phase 2 | terminated | Apr 12, 2011 | Lucas Vieira dos Santos | Low accrual | Enrollment / accrual |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who… | Phase 1 | terminated | Nov 6, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01666431 | Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of… | Phase 2 | terminated | Aug 16, 2012 | University of Zurich | not stated | Not stated |
| NCT01465815 | Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous… | Phase 1 / Phase 2 | withdrawn | Nov 7, 2011 | OHSU Knight Cancer Institute | Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and OSI-906… | Safety / toxicity |
| NCT01254734 | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck… | N/A | terminated | Dec 7, 2010 | City of Hope Medical Center | The study will be rewritten as a data registry study | Other (stated, no rule matched) |
| NCT02254044 | Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell… | Phase 1 | terminated | Oct 1, 2014 | Boehringer Ingelheim | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 10, 2017source: clinicaltrials